• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Shire Announces Sale of Oncology Business to Servier for $2.4 Billion


Shire (Dublin, Ireland) has entered into a definitive agreement to sell its oncology business to Servier (Neuilly-sur-Seine, France) for $2.4 billion. 

Under the terms of the agreement, Servier has agreed to acquire Shire’s oncology business for a total consideration of $2.4 billion, in cash, upon completion. In 2017, the oncology business generated revenues of $262 million. The transaction covers the transfer of Shire's in-market products Oncaspar and ex-U.S. rights to Onivyde. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL, and early stage immuno-oncology pipeline collaborations.

Shire CEO, Flemming Ornskov, commented: “While the oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire’s longer-term strategy.We will continue to evaluate our portfolio for opportunities to unlock further value and sharpen our focus on rare disease leadership with selective disposals of non-strategic assets.

Olivier Laureau, Servier Group President, said: “The acquisition of Shire's oncology franchise enables Servier to meet its strategic ambitions to become a global key player in oncology. As an essential step in the evolution of the Group, this acquisition allows us to establish a direct commercial presence in the United States, the world's leading pharmaceuticals market, and to strengthen our portfolio of marketed products in the territories where Servier is already present."


Related Videos
Related Content